EXHIBIT
      10.1    

    


    LETTER
      AGREEMENT BETWEEN Consortium Service Management Group, Inc. (“CSMG”) and Live
      Tissue Connect, Inc. (“LTC”)

    


    January
      4, 2008

    


    The
      following is the agreed structure between CSMG and LTC for the continuation
      of
      the R&D and marketing of the Live Biological Tissue Bonding project (“Tissue
      Bonding Project”).

    


    On
      May
      23, 2002 CSMG formed a subsidiary LTC, taking in outside shareholders that
      will
      own 14% of LTC. LTC and CSMG agree that it is imperative that the work of the
      Tissue Bonding Project continue and CSMG agrees to continue the project and
      advance funds as available to continue the project. It is agreed that effective
      from 5-23-06 all expenses and costs advanced by CSMG on the Tissue Bonding
      Project, paid by CSMG shall be carried on the books of LTC as a liability and
      accrue interest and begin accruing at the rate of 8% per annum on July 1, 2008.
      These costs effective July 1, 2008 including but are not limited to legal fees,
      patent costs, R&D costs, Kiev office support costs, travel, consulting, U.S.
      and Ukraine demonstration costs, equipment costs and U.S. development costs
      that
      are paid for by CSMG. Such expenses shall be reimbursed to CSMG from sources
      approved by the Board of Directors from cash flow, debt instruments, IPO, equity
      or debt placements or other means.

    


    In
      addition, once LTC is funded, LTC shall pay to CSMG the following amounts for
      services:

    


    
      	 	
              1)

            	
              A
                minimum management fee of $200,000.00 for the first year beginning
                on the
                date of the initial filing of S1and shall be negotiated each year
                thereafter but shall not be less than $200,000 annually.
                

            


    

    
      	 	
              2)

            	
              All
                costs of IAW Ukraine development estimated at $ 480,000.00 per year
                ($40,000 per month beginning September 2008) depending on devices
                being
                developed to be undertaken by IAW.

            


    

    
      	 	
              3)

            	
              A
                $300,000 one time fee on the 80th
                day following FDA approval

            


    

    
      	 	
              4)

            	
              Reimbursement
                of all Tissue Bonding Project expenses since 5-23-06 for LTC. Interest
                in
                the form of an 8% interest accrual will begin July 1, 2008 and to
                be paid
                from financing or revenues as those funds are available to
                LTC.

            


    

    
      	 	
              5)

            	
              After
                first 510K submittal and beginning in July 2008, LTC is to pay the
                greater
                of a minimum annual royalty fee of $220,000.00 or a minimum royalty
                of 2%
                of the adjusted retail price of all sales including those products
                marketed and distributed by other companies for sales and 2 % any
                LTC
                license fees received from other companies. First payment shall be
                paid no
                later than the 80th
                day following FDA approval. 

            


    

    
      	 	
              6)

            	
              LTC
                shall pay a portion of the annual costs of the CSMG Kiev office for
                Kiev
                support attributed to LTC work which is estimated at LTC share of
                $60,000.00 per year.

            


    

    


    Executed
      this 44th
      day of
      January 2008.

    


    
      	
              FOR
                CSMG:

            	 	
              FOR
                LTC:

            
	 	 	 
	
              /s/
                Herman Hohauser

            	 	
              /s/
                Donald S. Robbins

            
	
              Herman
                Hohauser

            	 	
              Donald
                S. Robbins

            
	
              Executive
                Vice President

            	 	
              Chairman
                and CEO

            


    

    


    CSMG
      OFFICES: Corpus
      Christi, TX - Kiev, Ukraine - Washington, DC - Atlanta, GA

    Contact:
      Donald S. Robbins Chairman and CEO 500 No. Shoreline, Suite 701 No., Corpus
      Christi, TX 78471-1007

    Telephone
      361-887-7546 FAX: 361-884-0792 E-Mail csmgtech@gmail.com

    WEB
      Site:
      www.csmgtechinternational.com